



## ASX Announcement

### Cancer Cell Journal Publication

---

**29 June 2020** – Race Oncology Limited (ASX: RAC) has become aware of a publication by Su, R et al. in Cancer Cell in July 2020 entitled “Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Invasion” prepared by scientists at the Beckman Research Institute of City of Hope, Los Angeles.

This publication relates to research conducted in relation to Bisantrone, the cancer drug which the Company is presently investigating in Phase II clinical trials.

The Company was not involved in, or aware of, the research findings of the manuscript. However, the Company will be evaluating the findings over the coming weeks and months to determine the extent to which they affect the Company and its own research activities.

As the Company has not been involved in the research referred to in the publication, it cautions investors not to trade on the basis of this information.

- ENDS -

#### About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrone. RAC has compelling clinical data for Bisantrone in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

John Cullity, Executive Chairman

[John.cullity@raceoncology.com](mailto:John.cullity@raceoncology.com)

Media contact:

Jane Lowe, IR Department

+61 411 117 774

[Jane.lowe@irdepartment.com.au](mailto:Jane.lowe@irdepartment.com.au)